Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI311 in thyroid eye disease
NCT06525506Phase 2Completed
- Sponsor
- Innovent Biologics
- Start
- Sep 2024
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of sycume in thyroid eye disease (TED) (4 arms), sponsored by Innovent Biologics. Primary endpoints: Mean change from Baseline in proptosis in the study eye at 12 weeks and Safety and Tolerability at 48 weeks. Started Sep 2024; status: completed.
02
Drugs
sycume
03
Conditions
thyroid eye disease (TED)
Beyond the preview
Go deeper on NCT06525506.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06525506.